ISPECIMEN INC (ISPC) 1.63 -0.08 (-4.4%)
1.63 -0.08 (-4.4%)
US45032V1089 - Common Stock
Fundamental Rating
We assign a fundamental rating of 3 out of 10 to ISPC. ISPC was compared to 48 industry peers in the Health Care Technology industry. ISPC scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. ISPC is quite expensive at the moment. It does show a decent growth rate.
Note: ISPC has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
The Piotroski-F score of ISPC is 4.00. This is a neutral score and indicates average health and profitability for ISPC.
VS Industry
Valuation
Valuation Rating
With a price book ratio of 0.65, ISPC is valued rather cheaply.
Compared to an average industry price book ratio of 2.67, ISPC is valued rather cheaply. On top of this, ISPC is cheaper than 89% of the companies listed in the same industry.
ISPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ISPC. No positive earnings are expected for the next year.
VS Industry
Price/Book (0.65) VS Industry: 89% outperformed.
13.58
0.29
Growth
Growth Rating
ISPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.07%, which is quite good.
Based on estimates for the next 5 years, ISPC will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.30% on average per year.
ISPC shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 36.38% yearly.
The Revenue is expected to grow by 0.75% on average over the next 5 years.
ISPC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -11.64%.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | 12.07% | 36.36% | 17.3% | N/A | N/A |
| Revenue | N/A | 36.38% | -11.64% | -14.64% | 0.75% | N/A | N/A |
Health
Health Rating
A Current Ratio of 8.55 indicates that ISPC has no problem at all paying its short term obligations.
The Current Ratio of ISPC is much better than the industry average of 2.45. ISPC has a better rating than 93% of its industry peers.
A Quick Ratio of 8.55 indicates that ISPC has no problem at all paying its short term obligations.
ISPC is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 2.38. ISPC has a better rating than 93% of its industry peers.
The Debt to Equity ratio of ISPC is in line with the industry averages.
The Piotroski-F score of ISPC is 4.00. This is a neutral score and indicates average health and profitability for ISPC.
Based on the Altman-Z score of -0.64, we must say that ISPC is in the distress zone and has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.09, ISPC is in worse financial health than its industry peers.
VS Industry
Debt/Equity (0.12) VS Industry: 51% outperformed.
4.07
0.00
Quick Ratio (8.55) VS Industry: 93% outperformed.
0.09
18.50
Current Ratio (8.55) VS Industry: 93% outperformed.
0.09
18.50
Altman-Z (-0.64) VS Industry: 35% outperformed.
-141.57
48.34
Dividend
Dividend Rating
ISPC does not give a dividend.
ISPECIMEN INC1.63
NASDAQ:ISPC (1/27/2023, 7:15:46 PM)-0.08 (-4.4%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Technology | ||
| Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | N/A N/A |
| Inst Owners | 5.3% | Inst Owner Change | 0% |
| Ins Owners | 8.78% | Ins Owner Change | 8.51% |
| Market Cap | 14.54M | Analysts | 82.22 |
| Price Target | 6.89 (322.7%) | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS beat(2) | N/A | Avg EPS beat(2) | -4.93% |
| Min EPS beat(2) | -8.93% | Max EPS beat(2) | -0.92% |
| EPS beat(4) | 1 | Avg EPS beat(4) | 30.33% |
| Min EPS beat(4) | -8.93% | Max EPS beat(4) | 135.65% |
| Revenue beat(2) | 1 | Avg Revenue beat(2) | -8.42% |
| Min Revenue beat(2) | -20.1% | Max Revenue beat(2) | 3.25% |
| Revenue beat(4) | 1 | Avg Revenue beat(4) | -12.75% |
| Min Revenue beat(4) | -23.1% | Max Revenue beat(4) | 3.25% |
| PT rev (1m) | 0% | EPS NQ rev (1m) | 0% |
| EPS NY rev (1m) | 0% | Revenue NQ rev (1m) | 0% |
| Revenue NY rev (1m) | 0% | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.65 | ||
| P/tB | 0.77 | ||
| EV/EBITDA | N/A |
| EPS(TTM) | -0.84 | EY | N/A |
| EPS(NY) | -1.3 | Fwd EY | N/A |
| FCF(TTM) | -0.98 | FCFY | N/A |
| OCF(TTM) | -0.78 | OCFY | N/A |
| SpS | 1.12 | BVpS | 2.51 |
| TBVpS | 2.13 | PEG (NY) | N/A |
| PEG (5Y) | N/A | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 54.26% |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | N/A |
| ROICexc growth 3Y | N/A | ROICexc growth 5Y | N/A |
| OM growth 3Y | N/A | OM growth 5Y | N/A |
| PM growth 3Y | N/A | PM growth 5Y | N/A |
| GM growth 3Y | 4.56% | GM growth 5Y | N/A |
| F-Score | 4 | Asset Turnover | 0.36 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 169.18% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.55 | ||
| Quick Ratio | 8.55 | ||
| Altman-Z | -0.64 |
| F-Score | 4 | WACC | 19.44% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 156.81% |
| Cap/Depr(5y) | N/A | Profit Quality(3y) | N/A |
| Profit Quality(5y) | N/A | ||
| EPS 1Y | 12.07% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -59.09% |
| EPS Next Y | 36.36% | EPS Next 2Y | 17.3% |
| EPS Next 3Y | N/A | EPS Next 5Y | N/A |
| Revenue growth 1Y | -11.64% | Revenue growth 3Y | 36.38% |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | -4.97% |
| Revenue Next Year | -14.64% | Revenue Next 2Y | 0.75% |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| EBIT growth 1Y | -106.56% | EBIT growth 3Y | N/A |
| EBIT growth 5Y | N/A | EBIT Next Year | -73.53% |
| EBIT Next 3Y | N/A | EBIT Next 5Y | N/A |
| FCF growth 1Y | -278.6% | FCF growth 3Y | N/A |
| FCF growth 5Y | N/A | OCF growth 1Y | -535.79% |
| OCF growth 3Y | N/A | OCF growth 5Y | N/A |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA